Table 3.
Agonistic tumor necrosis factor super family (TNF-SF) ligand-fusion proteins in clinical studies (www.clinicaltrials.gov)
| Targets | Name | Format | Tumor type | Combination | Phase | Status | Clinical ID | Information by |
|---|---|---|---|---|---|---|---|---|
| OX40 | MEDI6383 | Fcγ4(S228P)-TD-OX40L | Adv. solid tumors | +/– Durvalumab (αPD-L1) | I | Completed (07/2017) | NCT02221960 | MedImmune LLC |
| GITR | MEDI1873 | Fcγ1-TD-GITRL(N161D) | Adv. solid tumors | – | I | Completed (12/2018) | NCT02583165 | MedImmune LLC |
| FAP x 4-1BB | RO7122290 | (αFAP) Fab-Fcγ1mut-CH1/CL-4-1BBL | Metastatic colorectal cancer | Cibisatamab (αCEAxCD3) /Obinutuzumab (αCD20) | I/II | Recruiting | NCT04826003 | Hoffmann-La Roche |
| CD19 x 4-1BB | RO7227166 | (αCD19) Fab-Fcγ1mut-CH1/CL-4-1BBL | Lymphoma, non-Hodgkin | Obinutuzumab (αCD20)/Glofitamab (αCD20xCD3)/Tozilizumab (αIL-6R) | I | Recruiting | NCT04077723 | Hoffmann-La Roche |
| PDL-1 x OX40 | SL-279252 | PD1-Fcγ4-OX40L | Adv. solid tumors or lymphomas | – | I | Recruiting | NCT03894618 | Shattuck Labs, Inc. |
TD trimerization domain, adv. advanced